Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Yan Zi-Xun; Li Li; Wang Wen; OuYang Bin-Shen; Cheng Shu; Wang Li; Wu Wen; Xu Peng-Peng; Muftuoglu Muharrem; Hao Ming; Yang Su; Zhang Mu-Chen; Zheng Zhong; Li James; Zhao Wei-Li

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

【24h】

Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

机译：抗CD19嵌合抗原受体T细胞剂量升级研究中临床疗效和肿瘤微环境影响难治性B细胞非霍奇金淋巴瘤

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Anti-CD19 chimeric antigen receptor (CAR) T cells represent a novel immunotherapy and are highly effective in treating relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL). How tumor microenvironment influences clinical response to CAR T therapy remains of great interest.

机译：目的：抗CD19嵌合抗原受体（CAR）T细胞代表一种新型免疫疗法，并且在处理复发/难治性B细胞非Hodgkin的淋巴瘤（B-NHL）方面是高效的。肿瘤微环境如何影响汽车T治疗的临床反应仍然具有很大的兴趣。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2019年第23期|共9页
作者
Yan Zi-Xun; Li Li; Wang Wen; OuYang Bin-Shen; Cheng Shu; Wang Li; Wu Wen; Xu Peng-Peng; Muftuoglu Muharrem; Hao Ming; Yang Su; Zhang Mu-Chen; Zheng Zhong; Li James; Zhao Wei-Li;
展开▼
作者单位

Shanghai Jiao Tong Univ Sch Med Shanghai Rui Jin Hosp State Key Lab Med Genom Shanghai Inst;

Shanghai Jiao Tong Univ Sch Med Shanghai Rui Jin Hosp State Key Lab Med Genom Shanghai Inst;

JW Therapeut Shanghai Peoples R China;

Shanghai Jiao Tong Univ Sch Med Shanghai Rui Jin Hosp Dept Pathol Shanghai Peoples R China;

Shanghai Jiao Tong Univ Sch Med Shanghai Rui Jin Hosp State Key Lab Med Genom Shanghai Inst;

Shanghai Jiao Tong Univ Sch Med Shanghai Rui Jin Hosp State Key Lab Med Genom Shanghai Inst;

Shanghai Jiao Tong Univ Sch Med Shanghai Rui Jin Hosp State Key Lab Med Genom Shanghai Inst;

Shanghai Jiao Tong Univ Sch Med Shanghai Rui Jin Hosp State Key Lab Med Genom Shanghai Inst;

Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

JW Therapeut Shanghai Peoples R China;

JW Therapeut Shanghai Peoples R China;

Shanghai Jiao Tong Univ Sch Med Shanghai Rui Jin Hosp State Key Lab Med Genom Shanghai Inst;

Shanghai Jiao Tong Univ Sch Med Shanghai Rui Jin Hosp State Key Lab Med Genom Shanghai Inst;

JW Therapeut Shanghai Peoples R China;

Shanghai Jiao Tong Univ Sch Med Shanghai Rui Jin Hosp State Key Lab Med Genom Shanghai Inst;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma [J] . Yan Zi-Xun, Li Li, Wang Wen, Clinical cancer research: an official journal of the American Association for Cancer Research . 2019,第23期

机译：抗CD19嵌合抗原受体T细胞剂量升级研究中临床疗效和肿瘤微环境影响难治性B细胞非霍奇金淋巴瘤
2. Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma [J] . Bone marrow transplantation . 2020,第6期

机译：在抗CD19嵌合抗原受体T细胞治疗中的PD-1抑制快速肿瘤回归耐火弥漫性大B细胞淋巴瘤
3. A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CART-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma [J] . Shah Nirav N., Zhu Fenlu, Taylor Carolyn, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：第1阶段研究双靶向，串联抗CD19，抗CD20嵌合抗原受体改性T（CART-T）细胞的护理点，用于复发，难治性，非霍奇金淋巴瘤
4. Main Issues and Current Strategies in Enhancing the Efficacy of Chimeric Antigen Receptor T-Cell Therapy among Tumor Treatments [C] . Zhengting He International Conference on Frontiers of Biological Sciences and Engineering . 2020

机译：提高嵌合抗原受体T细胞治疗肿瘤治疗疗效的主要问题及目前策略
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma [O] . Yaqing Cao, Wenyi Lu, Rui Sun, 2007

机译：抗CD19嵌合抗原受体T细胞与Nivolumab组合可安全有效地治疗复发/难治性B细胞非霍奇金淋巴瘤
7. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE) [O] . Philip George, Nathaniel Dasyam, Giulia Giunti, 2020

机译：第三代抗CD19嵌合抗原受体T细胞，其掺入TLR2结构域，用于复发或难发的B细胞淋巴瘤：I阶段临床试验方案（启用）

Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

摘要

著录项

相似文献

相关主题

期刊订阅